This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Ware, J. L. Articles by Webb, K. S. Search for Related Content PubMed PubMed Citation Articles by Ware, J. L. Articles by Webb, K. S.

Production of Monoclonal Antibody Pro3 Recognizing a Human Prostatic Carcinoma Antigen¹

Department of Surgery, Division of Urology, Duke University Medical Center [J. L. W., D. F. P., S. F. P., K. S. W.], and the Verterans Administration Hospital [D. F. P., S. F. P.], Durham, North Carolina 27710

The monoclonal antibody Pro3 recognizes an antigen concentrated in human primary prostatic carcinoma tissue removed surgically. Although the antigen was detectable in extracts of human normal and malignant nonprostatic tissue, as well as in benign prostate tissue, quantitative absorption analysis revealed a substantially greater quantity of the antigen in malignant prostate tissue. The antigen recognized by Pro3 in primary prostatic carcinoma has an apparent nonreduced molecular weight of 175,000 and an apparent subunit molecular weight of 54,000. This antigen, p54, appears to be present on the surface of cultured prostatic tumor cells of the PC-3 cell line, but its location in vivo has not been defined. Successful competition between Pro3 and prostatic carcinoma patient serum immunoglobulin for a M_r 54,000 antigen (reduced molecular weight) present in prostatic carcinoma tissue extract suggests that p54 may play a significant role in the immunobiology of prostatic carcinoma. Pro3 has potential as a sensitive probe for an antigen relevant to human tumor biology.

¹ Supported by Grant CA 22902 from the National Cancer Institute and by the Medical Research Service of the Veterans Administration.

² Recipient of NIH Postdoctoral Fellowship F32 GM07469. To whom requests for reprints should be addressed.

Received 5/29/81. Accepted 12/16/81.